drugset / Trial / NCT04848662

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

NCT04848662

Phase 1 Completed 12 enrolled Bond Avillion 2 Development LP
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.

Timeline

Start
2021-05-06
Primary completion
2021-07-05
Completion
2021-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Budesonide Small molecule 1 mg Inhaled
Background Salbutamol Unknown 180 ug Inhaled

Indications